Clik here to view.
BioTime Provides Financing and Product Development Update
ALAMEDA, Calif. BioTime, Inc. (NYSE MKT: BTX) today announced the results of its capital raising activities since October 1, 2013 through its $25 million Controlled Equity Offering facility, and...
View ArticleClik here to view.
（株）STC Life， 干细胞研究治疗中心成功治疗 脑中风患者
首尔, 韩国 (美国商业资讯)– (株) stclife（董事长：李桂浩）97.7生命科学研究院（院长：郑元柱），成功地使用间充质干细胞治疗了脑中风患者。 脑中风是大脑机能的部分或者全部，急促的障碍性疾病，持续时间长。除了脑出血之外，其他的诱发原因还没有找到。脑中风是由脑出血引发疾病的总称，一般是指会突然出现急促脑出血，意识模糊，肌肉麻痹的脑疾病。...
View ArticleClik here to view.
STC lifeが幹細胞研究治療センターで脳卒中患者の治療に成功
韓国・ソウル （ビジネスワイヤ） — STC Life Co., Ltd.（会長：KYE HO LEE)の幹細胞研究所と97.7 B&H Clinic（代表医師：WON JU JUNG）は、脳卒中患者の間葉系幹細胞治療を成功裏に完了しました。...
View ArticleClik here to view.
STC life, Ltd. Successfully Treats Stroke Patients at Stem Cell Research...
SEOUL, South Korea Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Representative Doctor: WON JU JUNG) successfully completed mesenchymal stem cell...
View ArticleClik here to view.
Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese...
CAMBRIDGE, Mass. Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an...
View ArticleClik here to view.
日本人患者を対象にした VS-6063 ( defactinib ) の第1相試験のデータをVerastem社が発表
米国マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — がん幹細胞の選択的殺傷によるがん治療の薬剤開発を中心に行っているVerastem 社 ( NASDAQ: VSTM ) は本日、日本人患者を対象に行われている VS-6063 ( defactinib )...
View ArticleClik here to view.
Catalent Announces Agreement for One of the First Regenerative Therapies to...
SOMERSET, N.J. Catalent Pharma Solutions, the global leader in advanced delivery technologies and development solutions for drug, biologic and consumer health products, today announced an agreement...
View ArticleClik here to view.
Clik here to view.
R-Tech Ueno: Announcement of Collaborative Research with Keio University for...
TOKYO R-Tech Ueno, Ltd. (JASDAQ:4573): We announce the launch of a collaborative research on graft-versus-host disease (GVHD) with Professor Kazuo Tsubota’s group, Department of Ophthalmology, Keio...
View ArticleClik here to view.
STC life, Co., Ltd. Successfully Treats Canadian Pulmonary Fibrosis Patient...
SEOUL, South Korea Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Representative Doctor: WON JU JUNG) successfully finished mesenchymal stem cell...
View ArticleClik here to view.
（株）STC Life, 97.7 B&H医院干细胞治疗中心成功治疗加拿大肺纤维症患者
首尔, 韩国 (美国商业资讯)– (株)STC Life(董事长: 李桂浩)的干细胞研究所和97.7 B&H医疗中心(代表院长: 郑元柱)宣布成功利用间充质干细胞治疗从加拿大卡尔加里访韩的肺纤维症(Pulmonary fibrosis)患者。 患者为85岁男性，患自体免疫疾患之一的肺纤维症大约3年了。...
View ArticleClik here to view.
资生堂致力于毛发再生的研究设施开张
Smart Multimedia Gallery Research at Shiseido Cell-Processing and Expansion Center (Photo: Business Wire) View and Share Photo Download Small 东京...
View ArticleClik here to view.
Nitto: New Anti-fibrosis Drug with Molecular Targeting DDS Completed Phase-1a...
OSAKA, Japan Nitto Denko Corporation (Nitto) (TOKYO:6988) (ISIN:JP3684000007) has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration...
View ArticleClik here to view.
President of Leading South Korean Biopharmaceutical Company Green Cross...
Smart Multimedia Gallery Byung-Geon Rhee, Ph.D., President of South Korean biopharmaceutical company Green Cross Holdings, joins Stemedica’s Board of Directors. (Photo: Business Wire) View and Share...
View ArticleClik here to view.
ChinaBio® Partnering Forum 2014 Program Is Uniquely Designed for Global Life...
CARLSBAD, Calif. & SUZHOU, China ChinaBio® Partnering Forum 2014, China’s largest life science partnering event, will be held in one week, May 7–8, in Suzhou, China. The 2014 event kicks off...
View ArticleClik here to view.
Paul A. Friedman博士加入Verastem董事会
马萨诸塞州剑桥 (美国商业资讯)–Verastem, Inc. (NASDAQ:VSTM)专注于发现和开发以标靶疗法杀死癌症干细胞的抗癌药物，该公司今天宣布，Paul A. Friedman, M.D.加入公司董事会。 Verastem执行董事Christoph Westphal, M.D.,...
View ArticleClik here to view.
ポール・A・フリードマン医師がVerastem取締役会に加わる
米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — がん幹細胞の選択的殺傷によるがん治療薬の創薬・開発に傾注するVerastem（NASDAQ:VSTM）は本日、ポール・A・フリードマン（M.D.）を取締役に任命したと発表しました。...
View ArticleClik here to view.
NuGEN Launches Target Enrichment Technology that Delivers Improvements in NGS...
SAN CARLOS, Calif. NuGEN Technologies, Inc., a market leader in the development of solutions for Next Generation Sequencing (NGS) applications, has launched a novel technology to better enable...
View ArticleClik here to view.
New Bone Marrow Transplantation Technique Offered in Thailand by Phyathai 2...
BANGKOK Bone marrow transplantation used to require a donor who is the recipient’s sibling, parent or child with 50% HLA matching. At the Oncology Center of Phyathai 2 International Hospital, a new,...
View ArticleClik here to view.
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative...
ALAMEDA, Calif. BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies. The patents issued in Australia, Canada, China, Japan, and the...
View Article